Ihybes 150 Agimexpharm Treatment of Definitely Ath artery hypertension (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Irbesartan

Ingredient

Composition information	Content
Irbesartan	150mg

Uses

indications

Ihybes 150 drug is indicated in the following cases:

Treatment of idiopathic artery hypertension, especially for cases of using enzyme inhibitors and coughs and to reduce the risk of dullness in people with left ventricular hypertrophy. Irbesartan inhibits the physiological effects of Angiotensin II, both the effect of aldosteron and vasoconstriction, selecting AT1 receptor of Angiotensin II in many tissues, including the adrenal and smooth muscle contraction of the vascular wall.

When using Irbesartan with the recommended dose of blood potassium concentration does not change much unless there is kidney failure and/or heart failure.

Medications that lower blood pressure but the heart frequency changes very little. Hypotension effect depends on the dose and tend to not lower when taking a dose higher than 300 mg/time per day. The maximum lower blood pressure is about 3-6 hours after drinking. Anti -hypertension effect maintained at least 24 hours. The anti -hypertension effect is manifested within 2 weeks. The maximum efficiency is achieved within 4-6 weeks from the beginning of treatment and maintenance when long -term treatment. If the blood pressure stops gradually returning to the original value, but there is no sudden serious illness when stopping the drug.

Pharmacokinetics

absorption

After drinking, Irbesartan is quickly absorbed through the gastrointestinal tract with bioavailability of 60 - 80%. Food does not change much of the bioavailability of the drug. The peak concentration of plasma is reached about 1-2 hours after 1 dose of oral. The concentration of medication in the blood reaches a stable equilibrium after 3 days of taking the drug.

Distribution

The ratio of plasma protein is about 96%. The distribution of the drug is about 53 - 93 liters.

Metabolism

Irbesartan is partially specialized in the liver mainly by Cytochrom P450 ISOENZYM CYP 2C9 and possibly by both conjugated with glucuronic acid. Metabolic products are not active.

Elimination

Irbesartan and metabolites are eliminated through bile and urine, after taking about 20% of the amount of excretion of urine in the form of metabolism and less than 2% in non -metabolic form. Semi -exhaust life is 11 - 15 hours.

Before taking Ihybes 150 Agimexpharm Treatment of Definitely Ath artery hypertension (3 blisters x 10 tablets)

How to use

oral medication.

Dosage

Irbesartan's dosage is adjusted for each patient based on clinical response, oral medication in, before or after meals.

Treatment of hypertension

For patients who do not control the blood pressure at the dose of 150 mg x 1 time/day, the dose of 300 mg x 1 time/day. Can be combined with other high blood pressure treatments. Especially when combined with diuretics such as hydrochlorothiazid has shown to increase the effects of Irbesartan.

Treatment of kidney disease in people with type 2 diabetes with hypertension

Use the maintenance dose of 300 mg x 1 time/day (in patients who have started the starting dose of 150 mg 1 time/day).

kidney failure

No dose adjustment in people with renal impairment. Do not use this medication in patients with dialysis (due to the starting dose of 75 mg/day).

Reducing blood volume

When a decrease in blood volume or dehydration and salt, it is necessary to overcome these phenomena before using Irbesartan.

Hepatic failure

No dose adjustment for patients with mild and medium liver failure. There is no clinical experience for patients with severe liver failure.

Children

Not yet determined about the safety and effectiveness of Irbesartan in children.

Dosage should be adjusted after 1-2 months if the blood pressure is not controlled. May need treatment for many months to control the blood pressure well.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

The dose of up to 900 mg/day for adults for 8 weeks does not cause any toxic signs. In case of overdose, clinical symptoms are likely to occur, hypotension and tachycardia; Slow heart rate can also occur.

How to handle

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Ihybes 150, you may experience unwanted effects (ADR).

Common, ADR> 1/100

Neurological: dizziness; headache and hypotension.

cardiovascular: hypotension.

Uncommon, 1/1000

Skin and subcutaneous tissue: skin rash, urticaria, itching, angioedema.

Metabolism: Increase liver enzyme; hyperboly.

musculoskeletal: muscle pain, joint pain.

Rare, 1/10,000

Respiratory: cough, respiratory disorders.

musculoskeletal: back pain.

digestive: digestive disorders.

Other: fatigue, neutropenia ...

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Ihybes 150 drug contraindicated in the following cases:

Hypersensitivity to one of the ingredients of the drug.

Pregnant women.

Women who are breastfeeding.

Caution when using

reducing blood volume

There may be symptoms of hypotension, especially after taking the first dose, in patients with blood volume reduced such as salt loss and water due to strong diuretic groups, salt -limiting diet, diarrhea or vomiting. Such cases need to adjust these conditions before starting treatment with Irbesartan.

Renal artery stenosis

There is a risk of increased severity of hypotension and renal failure when the patient has narrowed kidney narrowing on both sides or the artery stenosis of a functional kidney treated with drugs that act on the renin-angiotensin-aldosterone system.

kidney failure and kidney transplant

When taking Irbesartan for patients with renal impairment, regular testing of potassium and creatinine should be checked in serum.

Hyperbonia

may experience hyperkalemia when using Irbesartan, especially those with heart and kidney function. Potassium concentration should be regularly checked regularly in these patients. Avoid simultaneous use of Irbesartan with diuretics keeping potassium.

Mitricous valve stenosis and aortic valve stenosis, hypertrophic myocardial disease

Particularly cautious for patients with mitral stenosis or aortic valve stenosis, or hypertrophic cardiomyopathy.

Increase Aldosteron Tien Phat

It is not recommended to use Irbesartan.

The ability to drive and operate machinery

should be cautious when driving or operating machinery because it may occur dizzy and tired during treatment with this drug.

Pregnancy

Contraindicated to use this drug for pregnant women. In the first 3 months of pregnancy may affect the growth and development of the fetus or have adverse effects on the fetus.

The period of breastfeeding

contraindicated to use iHybes for breastfeeding women.

Interactive drug

with other anti -hypertension drugs

Other anti -hypertension drugs may increase the hypotension of Irbesartan; However, Irbesartan can still be combined with other anti -hypertension drugs, such as beta blockers, calcium blockers or thiazide diuretics. An advance treatment with high doses of diuretics can create a decrease in blood volume and the risk of hypotension when taking Irbesartan.

Potassium supplements or potassium diuretics

Concentric use of this drug with diuretics keep potassium or potassium supplements increases the concentration of potassium.

lithium

Increased serum and recovery lithium concentration has been reported when combined with transferred enzyme inhibitors. It is necessary to monitor the kidneys that serum lithium concentration is needed if this combination is necessary.

Other interactive information

Digoxin's

pharmacokinetics does not change when used in combination with 150 mg of Irbesartan in healthy people.

Irbesartan pharmacokinetics are not changed when combined with hydroelorothiazid.

Irbesartan is metabolized by Cytochrom P450, so the interaction may occur when used with drugs on this enzyme.

Storage

temperature below 30 ° C, avoid moisture and light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.